EDIT

Editas Medicine Inc

2.70

Sep 11 • 3:59 PM ET +0.05 (1.89%)

2.70

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: NTLA CRSP PRME DTIL RGNX ABEO SLN MGTX SLDB VYGR

| Held by: VTI IWM VXF IBB IWO IWO VTWO SCHA VHT IWC

Index	RUT
Market Cap	414.67M
Enterprise Value	274.27M
Income	-73.95M
Sales	47.01M
Book/sh	0.69
Cash/sh	1.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	87
IPO	Feb 03, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	8.82
P/B	3.94
P/C	1.96
P/FCF	-
EV/EBITDA	-
EV/Sales	5.83
Quick Ratio	3.19
Current Ratio	3.19
Debt/Eq	0.68
LT Debt/Eq	0.54
Option/Short	Yes / Yes

EPS (ttm)	-0.74
EPS next Y	-0.73
EPS next Q	-0.19
EPS this Y	56.74%
EPS next Y	6.81%
EPS next 5Y	24.69%
EPS past 3/5Y	17.49% 1.84%
Sales past 3/5Y	27.15% -14.89%
EPS Y/Y TTM	73.89%
Sales Y/Y TTM	20.83%
EPS Q/Q	75.77%
Sales Q/Q	232.31%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	44.55% 317.74%

Insider Own	9.80%
Insider Trans	-0.19%
Inst Own	69.35%
Inst Trans	24.22%
ROA	-33.02%
ROE	-118.82%
ROIC	-45.50%
Gross Margin	94.84%
Oper. Margin	-177.56%
Profit Margin	-157.32%
SMA20	-10.64%
SMA50	-9.60%
SMA200	3.10%
Trades

Shs Outstand	153.53M
Shs Float	138.53M
Short Float	21.82%
Short Ratio	12.70
Short Interest	30.23M
52W High	4.54 -40.49%
52W Low	1.66 62.65%
Volatility	6.61% 7.07%
ATR (14)	0.21
RSI (14)	41.36
Beta	2.00
Rel Volume	1.04
Avg Volume	2.38M
Volume	2,463,715

Perf Week	-12.34%
Perf Month	-4.93%
Perf Quarter	10.66%
Perf Half Y	6.30%
Perf YTD	31.71%
Perf Year	-0.37%
Perf 3Y	-70.56%
Perf 5Y	-95.92%
Perf 10Y	-83.65%
Recom	2.27
Target Price	4.88
Prev Close	2.65
Price	2.70
Change %	1.89%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-18-26	Initiated	Ladenburg Thalmann	Buy	$6
Apr-28-25	Initiated	H.C. Wainwright	Buy	$3
Dec-16-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-13-24	Downgrade	Truist	Buy → Hold
Dec-13-24	Downgrade	Stifel	Buy → Hold	$11 → $3
Dec-13-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$7 → $4
Nov-25-24	Downgrade	BofA Securities	Buy → Underperform	$13 → $1
Nov-06-24	Upgrade	Evercore ISI	In-line → Outperform
Nov-04-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13

Show Previous Ratings

Sep-09-26 09:00AM	Editas Medicine Reports Inducement Grants to New Chief Medical Officer (GlobeNewswire) -8.58%
Sep-08-26 07:00AM	Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer (GlobeNewswire) -6.19%
Sep-01-26 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-26 05:04PM	Editas: Q2 Earnings Snapshot (Associated Press) +5.45%
04:01PM	Editas Medicine Announces Second Quarter 2026 Results and Business Updates (GlobeNewswire)
04:15PM	Loading…
Aug-04-26 04:15PM	Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. (GlobeNewswire)
May-28-26 04:01PM	Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference (GlobeNewswire)
May-26-26 09:05AM	Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering (GlobeNewswire) +11.59%
06:15AM	Editas Medicine Announces Proposed Public Offering (GlobeNewswire)
06:01AM	Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress (GlobeNewswire)
May-14-26 06:01AM	Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting (GlobeNewswire)
May-05-26 07:16AM	Editas: Q1 Earnings Snapshot (Associated Press)
07:00AM	Editas Medicine Announces First Quarter 2026 Results and Business Updates (GlobeNewswire)
Apr-27-26 04:31PM	Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences (GlobeNewswire) +5.88%
Mar-27-26 07:00AM	Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference (GlobeNewswire)
11:09AM	Loading…
Mar-10-26 11:09AM	EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y (Zacks) +13.79%
Mar-09-26 08:15AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +16.00%
07:11AM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates (GlobeNewswire)
Feb-23-26 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.59%
Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks) +6.56%
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 10:15AM	AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo (Zacks)
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
Nov-14-25 09:40AM	Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks) +5.56%
Nov-10-25 08:25AM	Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:24AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Editas Medicine Announces Third Quarter 2025 Results and Business Updates (GlobeNewswire)
Nov-07-25 07:10AM	Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates (Zacks) -8.18%
Nov-06-25 06:10PM	Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-25 09:00AM	Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 05:15PM	Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-09-25 11:01AM	Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress (GlobeNewswire)
Oct-06-25 09:00AM	Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-29-25 12:56AM	Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program (Insider Monkey) +8.64%
Sep-25-25 09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
Sep-11-25 11:30AM	Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? (Zacks) +5.86%
Sep-03-25 09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 07:00AM	Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate (GlobeNewswire)
Aug-28-25 04:01PM	Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate (GlobeNewswire)
Aug-27-25 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 07:50AM	Why Editas Medicine Stock Was Skyrocketing This Week (Motley Fool)
Aug-13-25 07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire) +34.50%
Aug-12-25 05:15PM	Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:14PM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Editas Medicine Announces Second Quarter 2025 Results and Business Updates (GlobeNewswire)
03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Can This Beaten-Down Stock Bounce Back? (Motley Fool)
Aug-11-25 08:15AM	Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-30-25 05:40PM	MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-03-25 09:09AM	Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data (Insider Monkey)
Jun-28-25 05:04AM	Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? (Motley Fool)
Jun-27-25 08:15AM	2 Beaten-Down Stocks to Avoid (Motley Fool) +7.55%
Jun-17-25 10:07AM	Editas Medicine Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
Jun-12-25 02:01AM	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June (GlobeNewswire) +7.39%
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
May-25-25 06:00AM	1 Stock Down 97% That Could Double, According to Wall Street (Motley Fool)
May-15-25 07:30PM	Editas Medicine: A Cautionary Tale for Investors (Motley Fool) +8.24%
03:11AM	A new CFO tasked with taking scrappy Editas from last years layoffs into new gene editing territory (Pharma Voice)
May-14-25 09:31AM	Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June (GlobeNewswire) -8.00%
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-13-25 09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-12-25 05:45PM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.21%
04:48PM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	Editas Medicine Announces First Quarter 2025 Results and Business Updates (GlobeNewswire)
04:01PM	Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board (GlobeNewswire)
12:00PM	Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-05-25 04:01PM	Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May (GlobeNewswire) -6.10% -13.64%
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
Apr-28-25 04:31PM	Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks) -8.04%
Apr-03-25 10:48AM	Editas Medicine: Do The Risks Outweigh The Rewards? (Seeking Alpha) -5.08%
Mar-21-25 08:15AM	AstraZeneca deepens China investment; Editas loses CFO to Dyne (BioPharma Dive)
Mar-20-25 04:12PM	Editas Medicine promotes Amy Parison as CFO (SeekingAlpha)
04:01PM	Editas Medicine Announces Chief Financial Officer Transition (GlobeNewswire)
Mar-05-25 05:25PM	Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +16.48% -13.17%
04:19PM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates (GlobeNewswire)
Feb-24-25 09:00AM	Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March (GlobeNewswire)
Jan-14-25 09:30AM	Editas Medicine Outlines 2025 Strategic Priorities and Milestones (TipRanks)
Jan-13-25 09:00AM	Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities (GlobeNewswire) -7.94%
Jan-06-25 09:00AM	Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.72%
Dec-30-24 03:11PM	Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-14-24 07:01AM	Editas Medicine price target lowered to $8 from $10 at Baird (TipRanks)
Dec-13-24 02:15PM	Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% (Investing.com) -23.81%
01:26PM	Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts (GuruFocus.com)
06:44AM	Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 (Benzinga)
Dec-12-24 04:00PM	Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years (GlobeNewswire) -5.03%
12:37PM	Editas to lay off staff after search for sickle cell partner comes up empty (BioPharma Dive)
Dec-09-24 12:00PM	Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-24 11:30AM	Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? (Zacks)
Nov-26-24 06:50AM	Editas Medicine downgraded to Underperform from Buy at BofA (TipRanks) -7.14%

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.

PresidentDr. Gilmore O'Neill M.D.

Senior VP & CFOMs. Amy Parison

Executive VP & Chief Scientific OfficerDr. Linda C. Burkly Ph.D.

Co-Founder & Scientific Advisory Board MemberDr. Feng Zhang Ph.D.

Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Sep 03 '26	Sale	3.04	709	2,153	61,660	Sep 04 04:27 PM
Parison Amy	SVP, Chief Financial Officer	Sep 03 '26	Sale	3.04	453	1,376	13,839	Sep 04 04:25 PM
O'Neill Gilmore Neil	CEO	Sep 03 '26	Sale	3.04	5,124	15,563	243,189	Sep 04 04:22 PM
O'Neill Gilmore Neil	Officer	Sep 03 '26	Proposed Sale	3.28	5,100	16,728		Aug 31 04:11 PM
Burkly Linda	Officer	Sep 03 '26	Proposed Sale	3.28	700	2,296		Aug 31 04:09 PM
Parison Amy	SVP, Chief Financial Officer	Aug 03 '26	Sale	2.58	678	1,749	14,292	Aug 05 04:07 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 28 '26	Sale	2.67	4,928	13,158	62,369	Jul 29 04:51 PM
Burkly Linda	Officer	Jul 27 '26	Proposed Sale	2.88	5,500	15,840		Jul 21 04:37 PM
Parison Amy	SVP, Chief Financial Officer	Jun 03 '26	Sale	2.70	464	1,253	14,970	Jun 05 04:33 PM
O'Neill Gilmore Neil	CEO	Jun 03 '26	Sale	2.70	15,380	41,543	248,313	Jun 05 04:33 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jun 03 '26	Sale	2.70	731	1,975	67,297	Jun 05 04:32 PM
O'Neill Gilmore Neil	Officer	Jun 03 '26	Proposed Sale	3.08	15,000	46,200		May 29 04:40 PM
O'Neill Gilmore Neil	CEO	Mar 03 '26	Sale	2.02	5,394	10,894	263,693	Mar 04 04:56 PM
Parison Amy	SVP, Chief Financial Officer	Mar 03 '26	Sale	2.02	474	957	15,434	Mar 04 04:49 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Mar 03 '26	Sale	2.02	749	1,513	68,028	Mar 04 04:48 PM
O'Neill Gilmore Neil	Officer	Mar 03 '26	Proposed Sale	1.89	6,000	11,340		Feb 27 04:35 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Dec 03 '25	Sale	2.15	713	1,535	68,777	Dec 04 04:39 PM
O'Neill Gilmore Neil	CEO	Dec 03 '25	Sale	2.15	5,603	12,064	269,087	Dec 04 04:38 PM
Parison Amy	SVP, Chief Financial Officer	Dec 03 '25	Sale	2.15	461	993	15,908	Dec 04 04:38 PM
O'Neill Gilmore Neil	Officer	Dec 03 '25	Proposed Sale	2.50	7,000	17,500		Dec 01 05:06 PM

Open in Screener

XAIR

Beyond Air Inc

3.20

Sep 11 • 3:59 PM ET +0.13 (4.23%)

3.28

Aftermarket • 7:46 PM ET +0.08 (2.50%)

Healthcare Medical Devices USA Nano NASD

Peers: BMRA FEED HSCS INBS IVF NXL TNON AEMD NUWE VTAK

| Held by: VXF

Index	-
Market Cap	3.15M
Enterprise Value	12.37M
Income	-33.49M
Sales	7.69M
Book/sh	2.69
Cash/sh	15.47
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	Sep 23, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	0.41
P/B	1.19
P/C	0.21
P/FCF	-
EV/EBITDA	-
EV/Sales	1.61
Quick Ratio	3.12
Current Ratio	3.31
Debt/Eq	11.80
LT Debt/Eq	11.57
Option/Short	No / Yes

EPS (ttm)	-68.49
EPS next Y	-
EPS next Q	-3.31
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	52.44% 30.89%
Sales past 3/5Y	- 54.47%
EPS Y/Y TTM	71.34%
Sales Y/Y TTM	60.75%
EPS Q/Q	64.13%
Sales Q/Q	0.45%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-1.85% -8.35%

Insider Own	0.00%
Insider Trans	-
Inst Own	6.99%
Inst Trans	-0.91%
ROA	-109.80%
ROE	-561.77%
ROIC	-133.22%
Gross Margin	4.18%
Oper. Margin	-364.76%
Profit Margin	-435.71%
SMA20	-28.42%
SMA50	-42.94%
SMA200	-76.66%
Trades

Shs Outstand	0.74M
Shs Float	-
Short Float	-
Short Ratio	0.36
Short Interest	0.07M
52W High	55.60 -94.24%
52W Low	3.06 4.47%
Volatility	6.20% 10.85%
ATR (14)	0.52
RSI (14)	30.29
Beta	0.21
Rel Volume	0.32
Avg Volume	203.03K
Volume	64,462

Perf Week	-10.86%
Perf Month	-47.11%
Perf Quarter	-57.45%
Perf Half Y	-80.25%
Perf YTD	-77.96%
Perf Year	-92.92%
Perf 3Y	-99.75%
Perf 5Y	-99.92%
Perf 10Y	-
Recom	1.00
Target Price	18.33
Prev Close	3.07
Price	3.20
Change %	4.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-01-26	Initiated	Lake Street	Buy	$10
Jul-17-25	Initiated	D. Boral Capital	Buy	$11
Jun-25-24	Downgrade	BTIG Research	Buy → Neutral
Jul-28-23	Initiated	Piper Sandler	Overweight	$10
Jun-15-23	Initiated	BTIG Research	Buy	$15
Apr-28-21	Initiated	Truist	Buy	$12
Oct-22-19	Initiated	Oppenheimer	Outperform	$9

Sep-02-26 08:00AM	Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-31-26 08:00AM	Beyond Air Receives FDA Breakthrough Device Designation for LungFit GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) (GlobeNewswire) -11.38%
Aug-25-26 07:00AM	Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments (GlobeNewswire)
Aug-13-26 07:09PM	Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strategic Financing and Pipeline ... (GuruFocus.com) +14.38% -8.74%
05:08PM	Beyond Air, Inc. Q1 2027 Earnings Call Summary (Moby)
07:00AM	Loading…
07:00AM	Beyond Air Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update (GlobeNewswire)
Aug-04-26 08:00AM	Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026 (GlobeNewswire)
Jul-30-26 07:00AM	Beyond Air Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-27-26 08:30AM	Beyond Air, Inc. Q4 2026 Earnings Call Summary (Moby)
Jun-26-26 03:00PM	Beyond Air Inc (XAIR) Q4 2026 Earnings Call Highlights: Revenue Surge and Path to Profitability (GuruFocus.com)
07:00AM	Beyond Air Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-22-26 04:01PM	Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast (GlobeNewswire) +13.61% +14.43%
Jun-10-26 08:00AM	Beyond Air, Inc. Urges Stockholders to Vote "FOR" All Proposals Ahead of the Upcoming Special Meeting (GlobeNewswire)
Jun-01-26 08:00AM	Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing (GlobeNewswire) +5.70%
Apr-20-26 08:00AM	Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 (GlobeNewswire)
08:00AM	Loading…
Apr-15-26 08:00AM	Beyond Air to Participate in the D. Boral Capital Global Conference 2026 (GlobeNewswire) -11.58%
Apr-01-26 09:00AM	Beyond Air Expands Commercial Access for LungFit PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO) (GlobeNewswire)
Mar-26-26 04:05PM	Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO (GlobeNewswire) -6.74%
Mar-17-26 04:35PM	Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial (GlobeNewswire)
Mar-11-26 07:00AM	Beyond Air to Participate in the 38th Annual Roth Conference in March (GlobeNewswire)
Mar-10-26 07:30AM	Beyond Air Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. (GlobeNewswire)
Mar-04-26 05:39AM	Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies (Insider Monkey)
Feb-20-26 08:00PM	Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... (GuruFocus.com) -7.34%
08:00AM	Beyond Air Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections (GlobeNewswire)
Feb-13-26 04:32PM	Beyond Air, Inc. Q3 2026 Earnings Call Summary (Moby)
07:30AM	Beyond Air Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-04-26 08:00AM	Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 (GlobeNewswire) -5.22%
Jan-27-26 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -7.53% -5.93%
Jan-26-26 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire) -9.88%
Jan-14-26 08:30AM	Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -14.16%
01:40PM	Loading…
Jan-13-26 01:40PM	Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments (Benzinga) +150.00%
07:30AM	XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership (GlobeNewswire)
Dec-30-25 07:30AM	Beyond Air Appoints Dan Moorhead as Chief Financial Officer (GlobeNewswire)
Dec-17-25 07:30AM	Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Germany and Brazil (GlobeNewswire)
Nov-26-25 04:30PM	Beyond Air Announces Transition of Chief Financial Officer (GlobeNewswire)
Nov-11-25 12:02AM	Beyond Air Inc (XAIR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... (GuruFocus.com) -16.09%
Nov-10-25 04:05PM	Beyond Air Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-05-25 08:00AM	Beyond Air Secures Up to $32 Million to Accelerate Growth (GlobeNewswire)
Oct-23-25 08:00AM	Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire)
Sep-22-25 08:00AM	Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference (GlobeNewswire) +5.38%
Sep-08-25 03:55PM	Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds (GlobeNewswire) +49.77%
08:00AM	NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults (GlobeNewswire)
Sep-03-25 08:00AM	Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-20-25 08:00AM	Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Japan (GlobeNewswire) -6.55%
Aug-13-25 03:11AM	Beyond Air Inc (XAIR) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... (GuruFocus.com) -22.47%
Aug-12-25 05:35PM	Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Beyond Air Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:45AM	Beyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com) +5.33%
Aug-07-25 06:20PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +5.63%
Jul-25-25 08:00AM	Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire)
Jul-22-25 07:30AM	Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc. (GlobeNewswire)
Jun-26-25 09:55AM	Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher (Zacks) -6.47%
Jun-18-25 03:01AM	Beyond Air Inc (XAIR) (Q4 2025) Earnings Call Highlights: Revenue Soars Amidst Strategic Global ... (GuruFocus.com) -29.02%
Jun-17-25 05:15PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +58.69%
04:01PM	Beyond Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-16-25 09:16AM	Beyond Air Inc (XAIR) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:00AM	Beyond Air Submits FDA PMA Supplement for Next Generation LungFit PH (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
May-28-25 05:20PM	Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-20-25 08:00AM	Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-24-25 04:05PM	Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) (GlobeNewswire)
Apr-21-25 04:05PM	NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism (GlobeNewswire)
Apr-15-25 04:05PM	NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board (GlobeNewswire)
Apr-09-25 04:05PM	Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit GO at Home (GlobeNewswire) +11.63%
Apr-01-25 08:00AM	NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders (GlobeNewswire) -8.22%
Mar-31-25 08:00AM	Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site (GlobeNewswire)
Mar-24-25 04:05PM	NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy (GlobeNewswire) +5.63%
Mar-23-25 08:38AM	Beyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-11-25 07:30AM	Beyond Air Announces Agreements Expanding Global Distribution of LungFit PH (GlobeNewswire)
Mar-06-25 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -6.06%
Feb-10-25 04:05PM	Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.37% -6.49%
Feb-07-25 07:10AM	Beyond Air Inc (XAIR) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-05-25 09:29AM	Beyond Air Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Jan-27-25 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) -7.83%
Jan-24-25 09:15AM	Beyond Air Announces LungFit PH Receives Market Authorization in Australia (GlobeNewswire)
Jan-06-25 08:00AM	Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (GlobeNewswire)
Dec-03-24 04:05PM	Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy (GlobeNewswire) +7.85% -8.67%
Dec-02-24 07:30AM	Beyond Air Receives CE Mark in Europe for the LungFit PH System (GlobeNewswire)
Nov-26-24 07:30AM	NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board (GlobeNewswire) +22.16%
Nov-14-24 04:05PM	Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +9.71% -5.38%
Nov-11-24 04:05PM	Beyond Air Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.64%
07:00AM	Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-08-24 07:06AM	Beyond Air Inc (XAIR) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.86%
Oct-29-24 04:22PM	Beyond Air Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) +11.65% +8.78%
Oct-07-24 07:00AM	Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -5.45%
Oct-02-24 07:30AM	Beyond Air Partners with Healthcare Links to Expand Access to LungFit PH System Through Group Purchasing Organizations and Integrated Delivery Networks (GlobeNewswire) +10.57%
Sep-28-24 07:40AM	Beyond Air to sell 40.39M shares at 51c in private placement (TipRanks)
07:35AM	Beyond Air terminates loan, security agreements with Avenue Capital (TipRanks)
Sep-27-24 07:34AM	Beyond Air Provides LungFit PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed (GlobeNewswire)
07:32AM	Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital (GlobeNewswire)
07:30AM	Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Sep-23-24 08:00AM	Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire) -6.08%
Aug-06-24 04:05PM	Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -17.38%
Jul-31-24 04:15PM	Beyond Air Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia (GlobeNewswire) -5.16%
Jul-23-24 04:05PM	Beyond Air to Report First Fiscal Quarter 2025 Financial Results on August 6 (GlobeNewswire) +5.29%
Jul-16-24 04:05PM	Beyond Air To Participate in the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-10-24 09:55AM	Beyond Air (XAIR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +5.59%
Jun-26-24 08:01AM	Beyond Air, Inc. (NASDAQ:XAIR) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-25-24 10:31AM	Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock (InvestorPlace) -51.54%
08:28AM	Why Is Beyond Air (XAIR) Stock Down 22% Today? (InvestorPlace)

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air, Beyond Cancer segments, and NeuroNos. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

CEO & DirectorMr. Robert Scott Goodman

Chief Financial OfficerMr. Daniel J. Moorhead CPA

Chief Operating OfficerMr. Michael A. Gaul

Principal Accounting Officer & ControllerMr. Denton Drewell

Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory BoardDr. Andrew R. Colin M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goodman Robert Scott	Chief Executive Officer	Jul 29 '26	Buy	5.76	34,722	199,999	34,822	Jul 31 06:55 PM
MOORHEAD DANIEL J	Chief Financial Officer	Jul 29 '26	Buy	5.76	4,340	24,998	4,340	Jul 31 06:21 PM

EDIT

Editas Medicine Inc

XAIR

Beyond Air Inc

Upgrade your Finviz experience